What metabolic or hematologic markers should we monitor in patients on IL-6 therapy?

What metabolic or hematologic markers should we monitor in patients on IL-6 therapy?

What metabolic or hematologic markers should we monitor in patients on IL-6 therapy?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Peter Nash, MD

Peter Nash, MD

Professor of Department of Medicine
Director of Rheumatology Unit on the Sunshine Coast
University of Queensland
Queensland, Australia